Immune checkpoint inhibitor-induced hepatitis injury: risk factors, outcomes, and impact on survival.

ABSTRACT:

Purpose

Immune checkpoint inhibitors (ICIs) are associated with a unique set of immune-related adverse events (irAEs). Few studies have evaluated the risk factors and outcomes of patients who develop ICI-induced hepatitis (ICIH).

Methods

We utilized an institutional database of patients with advanced cancers treated with ICI to identify patients with ICIH. irAEs were graded using the Common Terminology Criteria for Adverse Events v4. Overall survival (OS) was calculated from the date of ICI to death from any cause or the date of the last follow-up. OS with 95% confidence intervals were estimated using the Kaplan-Meier method and stratified by the occurrence of ICIH.

Results

We identified 1096 patients treated with ICI. The most common ICIs were PD1/L1 (n = 774) and CT

SUBMITTER: Miah A 

PROVIDER: S-EPMC10191203 | biostudies-literature | 2023 May

REPOSITORIES: biostudies-literature